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ABSTRACT 
 
 Inactivation of the tumor suppressor p53 is essential for the development and maintenance of cancer 
cells. Therefore, reactivation of p53 appears to be a promising strategy for anti-cancer therapy. We 
have previously identified the small molecule RITA that prevents interaction between p53 and its 
negative regulator Mdm2 by direct binding to p53 (Issaeva et al., 2004). RITA reactivates the 
transcriptional transactivation function of wild type p53 and induces p53-dependent apoptosis in vitro 
and in vivo.  
 
In this thesis we addressed the molecular mechanisms of RITA action. In particular, we investigated 
which signaling networks are important for RITA-mediated cancer cell killing, characterized 
p53/RITA interaction and studied the effect of RITA on mutant p53.  
 
We previously demonstrated that transactivation of pro-apoptotic genes is required for cell death 
induced by RITA-reactivated p53 (Enge et al., 2009). We found that the activation of pro-apoptotic 
targets is not sufficient for a full-scale induction of cell death by p53. Here, we showed that a 
dramatic and rapid downregulation of a number of critical oncogenes and oncogenic pathways by 
RITA-reactivated p53 is required for the induction of apoptosis. Importantly, our results indicate that 
induction of pro-apoptotic genes and inhibition of anti-apoptotic/survival genes represent two 
branches of p53 response, which are differentially regulated. Our results suggest that p53-mediated 
transrepression is more tightly controlled than transactivation and correlates with increased p53 and 
reduced Mdm2 abundance on chromatin.  
 
To address the molecular mechanism through which RITA interferes with Mdm2, we mapped RITA-
binding site in p53 using a series of deletion and point mutants. We found that RITA binds outside of 
the Mdm2 binding site and identified S33 and S37 as key p53 residues targeted by RITA. This 
implies that p53/Mdm2 interaction is prevented by RITA via allosteric mechanism. We propose that 
RITA/p53 binding induces a conformational trap locking Mdm2-contacting residues in an orientation 
unfavorable for the p53/Mdm2 binding. Moreover, we found that the conformational change induced 
by RITA prevents the binding of another p53 inhibitor, MdmX.  
 
Half of human tumors carry point mutations in the p53 gene that abolish p53 binding to DNA. This 
correlates with poor prognosis and often confers increased resistance to conventional chemo- and 
radiotherapy. The ability of RITA to induce a conformational change in p53 prompted us to test 
whether RITA can also restore mutant p53 activity. Here, we found that RITA suppressed the growth 
and induced apoptosis in a p53-dependent manner in a variety of cell lines that harbor different hot 
spot p53 mutations. Several known p53 target genes changed their expression in mutant p53-
expressing cells upon RITA treatment. Inhibition of mutant p53 prevented RITA-induced effects, 
suggesting the observed transcriptional response and cell death are dependent on mutant p53.  
 
In summary, our findings demonstrate, that p53 reactivated by the small molecule RITA induces 
ablation of oncogenic pathways crucial for the survival of cancer cells. RITA acts via an allosteric 
mechanism and restores the function of both wt and mutant p53. 
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